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OBJECTIVES The purpose of this study was to assess the efficacy and safety of beraprost sodium, an orally
active prostacyclin analogue, in New York Heart Association (NYHA) functional class II and
III patients with pulmonary arterial hypertension (PAH).
BACKGROUND Pulmonary arterial hypertension is a life-threatening disease for which continuous intrave-
nous infusion of prostacyclin has been proven effective. However, this treatment is associated
with serious complications arising from the complex delivery system.
METHODS In this double-blind, placebo-controlled study, 130 patients with PAH were randomized to
the maximal tolerated dose of beraprost (median dose 80 g four times a day) or to placebo
for 12 weeks. The primary end point was the change in exercise capacity assessed by the 6-min
walk test. Secondary end points included changes in Borg dyspnea index, cardiopulmonary
hemodynamics and NYHA functional class.
RESULTS Patients treated with beraprost improved exercise capacity and symptoms. The difference
between treatment groups in the mean change of 6-min walking distance at week 12 was
25.1 m (95% confidence interval [CI]: 1.8 to 48.3, p  0.036). The difference in the mean
change of Borg dyspnea index was 0.94 (95% CI: 1.63 to 0.24, p  0.009). In the
sub-group of patients with primary pulmonary hypertension, the difference in the mean
change of 6-min walking distance was 46.1 m (95% CI: 3.0 to 89.3, p  0.035).
Cardiopulmonary hemodynamics and NYHA functional class had no statistically significant
changes. Drug-related adverse events were common in the titration phase and decreased in
the maintenance period.
CONCLUSIONS Beraprost improves exercise capacity and symptoms in NYHA functional class II and III
patients with PAH and, in particular, in those with primary pulmonary hypertension. (J Am
Coll Cardiol 2002;39:1496–502) © 2002 by the American College of Cardiology Foundation
Pulmonary arterial hypertension (PAH) is defined, accord-
ing to the 1998 World Health Organization classification
(1), as a group of diseases characterized by a progressive
increase of pulmonary vascular resistance leading to right
ventricular failure and death (2,3). Pulmonary arterial hy-
pertension includes primary pulmonary hypertension (2,4)
and pulmonary hypertension associated with various condi-
tions such as collagen vascular diseases (5), congenital
systemic-to-pulmonary shunts (6), portal hypertension (7)
and human immunodeficiency virus (HIV) infection (8). All
these conditions share virtually identical obstructive patho-
logic changes of the pulmonary microcirculation (9). Pros-
tacyclin is an endogenous substance produced by vascular
endothelium that has vasodilating, antiplatelet aggregation
and antiproliferative effects (10–12). A dysregulation of
prostacyclin metabolic pathways has been demonstrated in
patients with PAH (13) and in experimental models of
pulmonary hypertension (14,15). Recently, therapy with
continuous intravenous prostacyclin (epoprostenol) has been
shown to improve symptoms and prognosis in New York
Heart Association (NYHA) functional class III and IV
patients with different types of PAH (16–20). However,
epoprostenol requires permanent intravenous catheters and
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portable pumps and is associated with several side effects
and potentially serious complications. For these reasons,
alternatives to intravenous prostacyclin have been sought,
and this has led to analogues, which can be administered
subcutaneously (treprostinol), by inhalation (iloprost) or
orally (beraprost sodium) (21).
Beraprost sodium is the first chemically stable and orally
active prostacyclin analogue (22). In experimental studies,
beraprost sodium has been shown to exert a protective effect
on the development of monocrotaline-induced pulmonary
hypertension (23). Uncontrolled and retrospective experi-
ences in patients with primary pulmonary hypertension have
preliminarily shown that long-term oral treatment with
beraprost sodium improves hemodynamics (24) and prog-
nosis (25).
We report on the results of a randomized, double-blind,
placebo-controlled, multicenter study designed to deter-
mine the effects of 12-week oral administration of beraprost
sodium on exercise capacity, symptoms and cardiopulmo-
nary hemodynamics in NYHA class II and III patients with
PAH.
METHODS
Patients selection. Patients eligible for this study were
males or females over 8 years of age with PAH (1) in
NYHA functional classes II and III, including primary
pulmonary hypertension, pulmonary hypertension associ-
ated with collagen vascular disease, congenital systemic-to-
pulmonary shunts, portal hypertension and HIV infection.
A baseline 6-min walking distance between 50 and 500 m,
a mean pulmonary artery pressure 25 mm Hg and a
pulmonary capillary wedge pressure 15 mm Hg were
required for inclusion. Patients were excluded if they had
received long-term treatment with other prostacyclin ana-
logues within one month of enrolment. The study was
conducted in accordance with good clinical practices, the
current version of the declaration of Helsinki and with local
regulations. The local ethics review committee approved the
protocol, and written informed consent was obtained from
all patients.
Study design. This study was designed as a prospective,
double-blind, randomized, placebo-controlled, 12-week
trial conducted in 13 centers in Europe. The first six weeks
of the study were considered as a titration period in which
the dose of beraprost sodium was increased weekly until the
maximal tolerated dose was achieved. Patients received one
tablet (20 g) of beraprost sodium or matching placebo four
times a day for the first week, and the dose was increased by
20 g or matching placebo four times a day each week. In
case of intolerable side effects, the dose was reduced to that
of the previous week, and this was considered as the
maximal tolerated dose. Therefore, the up-titration was
based on side effects and not on clinical efficacy, in order to
administer the highest tolerated dose. The maximal dose
allowed in the study was 120 g four times a day at week 6.
The maximal tolerated dose was kept constant during the
maintenance period between week 7 and week 12. Side
effects limiting dose increase were moderate to severe
flushing, headache and diarrhea and usually occurred 1 to
2 h after single-dose intake. All patients were enrolled in an
open-label study with beraprost sodium after the comple-
tion of the randomized study.
Outcome measures. Patients were evaluated at baseline,
week 6 and week 12. The primary efficacy parameter was
exercise capacity measured by the distance a patient could
walk in 6 min (6-min walk test) at week 12. The 6-min walk
test was performed after standardized procedures (26) 2 to
4 h after drug intake.
Secondary measures of efficacy included the Borg dyspnea
index (27) assessed immediately after completion of the
6-min walk test and cardiopulmonary hemodynamics mea-
sured by right heart catheterization at baseline and week 12.
Cardiac index (l/min/m2) was computed as cardiac output
divided by body surface area; pulmonary vascular resistance
index (U/m2) was calculated using standard formula: mean
pulmonary artery pressurepulmonary capillary wedge
pressure/cardiac index. Secondary measures of efficacy also
included the NYHA functional class and the reduction in
all-cause mortality or hospitalization for worsening of
symptoms related to pulmonary hypertension. Safety was
assessed by adverse event recording and laboratory assess-
ment.
Statistical analysis. The sample size was estimated under
the assumptions of a two-sided alpha probability of 0.05, an
80%-power, an expected treatment difference for the change
from baseline in 6-min walk test of 40 m and an SD of
70 m. Under these conditions, the study’s 1:1 randomization
required a sample size of at least 50 evaluable patients in
each group. Assuming a 10% drop-out rate, planned recruit-
ment was for a total of 110 patients (55 per group).
Analysis were performed in the intent-to-treat popula-
tion that included all patients who were randomized, re-
ceived at least one dose of study treatment and who also had
a valid assessment of the primary end point (change from
baseline in exercise capacity after 12 weeks of treatment)
after applying the imputation rules for missing data.
In the event that no data were available at week 12 for the
primary or secondary efficacy variable, the week 6 values or,
if lacking, the baseline values were carried forward and used
as values at week 12 (last observation carried forward). Two
additional methods for missing data imputation were pro-
spectively planned for the primary efficacy variable to ensure
robustness of the results: the “left censored data” and “worst
quartile” methods.
Abbreviations and Acronyms
CI  confidence interval
HIV  human immunodeficiency virus
PAH  pulmonary arterial hypertension
NYHA  New York Heart Association
1497JACC Vol. 39, No. 9, 2002 Galie` et al.
May 1, 2002:1496–502 Beraprost Sodium in Pulmonary Hypertension
The significance levels of the difference between treat-
ment groups for the 6-min walk test were evaluated with
analysis of covariance (ANCOVA) (i.e., analysis of variance
adjusted by baseline values, using the change from baseline
to week 12 for each patient [SAS, version 8, Cary, North
Carolina]). This test was performed at 5% two-tail level.
The changes from baseline to week 12 of Borg dyspnea
index and hemodynamic parameters were compared be-
tween treatment groups with ANCOVA. Changes from
baseline to week 12 in NYHA classification (ordinal scale)
were analyzed using Mantel-Haenszel method. Values with
a  symbol are the mean  SD. All the reported p values
were two-tailed.
RESULTS
One hundred thirty patients were included in the study
(65 beraprost/65 placebo). At the end of 12 weeks, mean
dose of drug was 80  35 g four times a day (median 
80 g four times a day) in the beraprost sodium group, and
the hypothetical dose in the placebo group was 111 22 g
four times a day.
Baseline characteristics. Baseline demographic, clinical
and hemodynamic characteristics of the two groups are
shown in Table 1. The groups did not differ significantly in
etiology of PAH, in NYHA functional class, in distance
walked at the 6-min walk test or in severity of pulmonary
hemodynamics. In the beraprost sodium group, there was a
nonsignificant trend toward a higher prevalence of patients
with primary pulmonary hypertension as well as a trend
toward a lower mean distance walked at baseline.
Exercise capacity. The distance walked in 6 min improved
in the beraprost sodium group from 362  94 m to 377 
106 m at week 6 and to 377  113 m at week 12. The
distance walked increased in the placebo group from 383 
93 m to 388  111 m at week 6 and decreased to 374 
121 m at week 12. The difference in mean distance walked
(beraprost sodium group  placebo group) at week 12
adjusted by baseline values was 25.1 m (95% confidence
interval [CI]: 1.8 to 48.3) in favor of beraprost sodium (p 
0.036) (Fig. 1). The significance of the improvement in
exercise capacity with beraprost sodium was confirmed if the
missing walking distance was replaced utilizing left censored
data (p  0.048) and worst quartile (p  0.046) methods.
The significance was confirmed also in the per-protocol
(standard) population (p  0.041).
Because the clinical hypothesis of an interaction between
treatment effect and the two sub-groups of patients with
primary pulmonary hypertension and associated forms of
pulmonary hypertension was suggested by an interaction
test (p  0.073 last observation carried forward, p  0.036
left-censored, p  0.044 worst quartile methods), a sub-
group analysis was performed (post-hoc analysis). In the
sub-group of patients with primary pulmonary hyperten-
sion, the distance walked in 6 min improved at week 12 in
the beraprost sodium group from 357  95 m to 380 
117 m and decreased in the placebo group from 406 79 m
to 383  125 m. The difference in mean distance walked
adjusted by baseline values (Fig. 2) was 46.1 m (95% CI: 3.0
to 89.3) in favor of beraprost sodium (p  0.035). In the
sub-group of patients with associated forms of pulmonary
hypertension, the distance walked in 6 min increased at
week 12 in the beraprost sodium group from 367 94 m to
373 110 m and was unchanged in the placebo group from
Table 1. Demographic and Hemodynamic Characteristics at
Baseline, According to Treatment Group*
Characteristic
Beraprost
(n  65)
Placebo
(n  65)
Age, yrs 45.8  16.3 45.1  14.4
Gender, no. (%)
Male 23 (35.4) 27 (41.5)
Female 42 (64.6) 38 (58.5)
Etiology, no. (%)
Primary pulmonary hypertension 35 (53.9) 28 (43.1)
Pulmonary hypertension associated with:
Congenital cardiac shunt 9 (13.8) 15 (23.1)
Portal hypertension 12 (18.5) 9 (13.8)
Collagen vascular diseases 5 (7.7) 8 (12.3)
HIV infection 4 (6.2) 5 (7.7)
NYHA functional class, no. (%)
II 31 (47.7) 33 (50.8)
III 34 (52.3) 32 (49.2)
6-min walk distance, m 362  94 383  93
Borg dyspnea score, Borg scale 3.6  2.4 3.5  2.4
Hemodynamic parameters
Right atrial pressure, mm Hg 8  5 9  6
Mean pulmonary artery pressure,
mm Hg
58  21 61  15
Cardiac index, l/min/m2 2.4  0.7 2.4  0.7
Pulmonary vascular resistance
index, U/m2
22.7  12.8 23.9  10.8
Treatment at inclusion, no. (%)
Anticoagulants 49 (75.4) 46 (70.8)
Diuretics 33 (50.8) 36 (55.4)
Calcium channel blockers 17 (26.2) 11 (16.9)
Digoxin 12 (18.5) 13 (20.0)
*Values with a  symbol are the mean  SD.
HIV  human immunodeficiency virus; NYHA  New York Heart Association.
Figure 1. Change in 6-min walking distance from baseline to week 6 and
week 12 in the placebo and beraprost groups. Values are expressed as mean
 standard error. p  0.036 for no difference between treatment groups
with analysis of covariance at week 12.
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366  100 m to 366  120 m. The difference in mean
distance walked adjusted by baseline values (Fig. 2) was
5.1 m (95% CI:19.5 to 29.6) in favor of beraprost sodium
(p  0.676).
Signs and symptoms. Borg dyspnea index improved (de-
creased) at week 12 in the beraprost sodium group from
3.6 2.4 m to 3.0 2.4 m and worsened (increased) in the
placebo group from 3.5  2.5 m to 3.9  2.8 m. The
difference in mean Borg dyspnea index adjusted by baseline
values (Fig. 3) was 0.94 (95% CI: 1.63 to 0.24) in
favor of beraprost sodium (p  0.009). In the primary
pulmonary hypertension sub-group, the difference in mean
Borg dyspnea index was 1.46 (95% CI: 2.63 to 0.28)
in favor of beraprost sodium (p  0.013) and in the
associated forms of pulmonary hypertension sub-group was
0.45 (95% CI: 1.31 to 0.40) in favor of beraprost
sodium (p  0.283).
At the end of 12 weeks, 16 patients (25%) treated with
beraprost sodium and 10 patients (15%) of the placebo
group showed improved NYHA functional class (p 
0.190).
During the 12-week study period, four patients (6%) in
the beraprost sodium group and three (5%) patients in the
placebo group either died or were hospitalized for worsening
Figure 2. Mean change from baseline in results of the 6-min walk test at week 12 in all patients (ALL), in patients with primary pulmonary hypertension
(PPH) and in patients with associated forms of pulmonary hypertension (APH). Analysis of covariance adjusted by baseline values showed that the mean
distance walked in 6 min increased in patients who received beraprost (solid bars) compared with patients who received placebo (open bars) in ALL (p 
0.036) and in PPH patients (p 0.035). No statistically significant changes were observed in APH patients (p 0.676). Numbers at the tops of the bars
exact mean rates; lines  standard error of the mean. N  the number of patients in each group.
Figure 3. Mean change in Borg dyspnea index from baseline to week 12 in all patients (ALL), in patients with primary pulmonary hypertension (PPH)
and in patients with associated forms of pulmonary hypertension (APH). Analysis of covariance adjusted by baseline values showed that Borg dyspnea index
improved (decreased) in patients who received beraprost (solid bars) and worsened (increased) in the placebo group (open bars) over 12 weeks in ALL (p
0.009) and in PPH patients (p 0.013). No statistically significant changes were observed in APH patients (p 0.935). Numbers at the tops of the bars
exact mean rates; lines  standard error of the mean. N  the number of patients in each group.
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of symptoms related to pulmonary hypertension. Two
patients died, one in the beraprost sodium group due to
progressive right heart failure and one in the placebo group
due to septic shock.
Cardiopulmonary hemodynamics. The changes in hemo-
dynamic measures from baseline to week 12 are shown in
Table 2. The beraprost and placebo treated patients had
small variations of hemodynamic parameters, and no statis-
tically significant changes were detected.
Safety and tolerability. Selected adverse events attributed
to the underlying disease or to the treatment are shown in
Table 3. Disease-related events had similar incidence in
patients receiving beraprost and in those receiving placebo.
Drug-related adverse events like headache, flushing, jaw
pain and diarrhea were more common in patients treated
with beraprost sodium and occurred mostly during the
six-week titration period. The incidence was markedly
reduced in the maintenance period.
Six patients (9%) in the beraprost sodium group and two
patients (3%) in the placebo group withdrew prematurely
from the study because of adverse events. No clinically
adverse changes in hematologic or biochemical variables
were seen in the beraprost sodium group. Liver transami-
nases increased by more than 0.6 times the upper normal
limits in four (6%) patients in the placebo group as com-
pared with none in the beraprost sodium group.
DISCUSSION
Exercise capacity. This double-blind, placebo-controlled,
12-week study demonstrated that the oral prostacyclin
analogue beraprost sodium improves exercise capacity and
symptoms in patients with PAH. As in other trials per-
formed in this patient population, the primary end point of
this study was the 6-min walking distance that has been
shown to be an independent predictor of mortality (16,28).
In our study the robustness of the 6-min walk test results
were confirmed by different statistical analysis. So far,
therapeutic trials in PAH have included more severely
compromised subjects in NYHA functional class III or IV
(16,18). For the first time, our study has included a larger
proportion (49% of overall population) of less severe pa-
tients in NYHA functional class II (Table 1). Interestingly,
no significant interaction was observed between NYHA
functional class and treatment effect, suggesting that the
favorable effects of beraprost sodium were similar in both
NYHA functional class II and III patients.
Sub-group analysis. Sub-group analysis has shown that
the improvement in the 6-min walk test was achieved only
in patients with primary pulmonary hypertension, while no
statistically significant changes were observed in the associ-
ated forms group (Fig. 2). The treatment effect observed in
NYHA class II and III patients with primary pulmonary
hypertension was 45 m. In a previous study with intravenous
epoprostenol, carried out in a more severe patient popula-
tion (NYHA functional class III and IV), the treatment
effect was 47 m (16).
The absence of significant improvement of exercise ca-
pacity in associated forms of pulmonary hypertension could
be attributed to different causes. Firstly, in this trial the
group of associated forms was heterogeneous including 36%
of patients with congenital systemic-to-pulmonary shunts,
32% with portal hypertension, 19% with collagen vascular
disease and 13% with HIV infection. Analysis of the effects
on each individual sub-group is prevented by the small
sample size. So far, a single controlled clinical study has
demonstrated a positive effect of epoprostenol on exercise
capacity in patients with pulmonary hypertension associated
Table 2. Changes From Baseline in Cardiopulmonary
Hemodynamic Measurements
Variables
Change From Baseline
p
Value*Beraprost Placebo
Right atrial pressure (mm Hg) 0  1 1  0 0.219
Systolic pulmonary artery
pressure (mm Hg)
2  2 2  2 0.058
Mean pulmonary artery
pressure (mm Hg)
1  1 1  1 0.216
Cardiac index (l/min/m2) 0.2  0.08 0.0  0.08 0.192
Pulmonary vascular resistance
index (U/m2)
1.3  0.83 0.3  0.83 0.188
Values are given as mean  standard error of the mean.
*Analysis of covariance.
Table 3. Incidence of Selected Adverse Events According to the Study Period
Event
Beraprost (n  65) Placebo (n  65)
Titration
(Week 1–6)
Maintenance
(Week 7–12)
Titration
(Week 1–6)
Maintenance
(Week 7–12)
Disease-related, no. (%)
Dizziness 5 (7.7) 0 (0.0) 5 (7.7) 2 (3.1)
Syncope 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.5)
Right heart failure 1 (1.5) 2 (3.1) 3 (4.6) 3 (4.6)
Treatment-related, no. (%)
Headache 44 (67.7) 11 (16.9) 11 (16.9) 1 (1.5)
Flushing 35 (53.8) 9 (13.8) 8 (12.3) 3 (4.6)
Jaw pain 18 (27.7) 3 (4.6) 1 (1.5) 0 (0.0)
Diarrhea 17 (26.2) 2 (3.1) 4 (6.2) 1 (1.5)
Leg pain 14 (21.5) 3 (4.6) 4 (6.2) 1 (1.5)
Nausea 13 (20.0) 4 (6.2) 3 (4.6) 2 (3.1)
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with scleroderma (18). Treatment with prostanoids of all
the other forms of associated pulmonary hypertension have
been evaluated in uncontrolled studies (17), and the favor-
able effects require further confirmations. Secondly, the
doses of beraprost sodium were substantially lower in
patients with associated forms of pulmonary hypertension
than in patients with primary pulmonary hypertension
(62  36 g four times a day vs. 96  35 g four times a
day, respectively). Dose increase was usually limited by
symptoms like headache, flushing and diarrhea, and it is
possible that patients with associated conditions are more
predisposed to these side effects. In fact, patients with portal
hypertension, HIV infection and collagen vascular disease
have a multi-organ involvement that could interfere with
beraprost sodium tolerability. It is unclear from our data if
the higher dose of beraprost sodium tolerated by patients
with primary pulmonary hypertension may explain the
better results obtained on 6-min walking distance. Finally, a
12-week study may be too short to demonstrate a beneficial
effect of prostanoid therapy in the associated forms group.
In fact, patients with pulmonary hypertension associated
with systemic-to-pulmonary shunt or to portal hypertension
(67% of associated forms in this trial) may show a slower
rate of clinical deterioration (29) and a longer preservation
of the cardiac output. This evidence is supported in our
study by the absence of a reduction of the 6-min walking
distance in placebo-treated patients with the associated
forms, whereas the placebo-treated patients with primary
pulmonary hypertension showed a significant decrease of
exercise capacity (Fig. 2).
Symptoms and outcome. In the overall population, the
improvement in the 6-min walking distance was associated
with a concomitant significant improvement in the percep-
tion of dyspnea, as assessed by the reduction of Borg
dyspnea score (Fig. 3). On the other hand, we observed no
statistically significant improvement of NYHA functional
class in patients treated with beraprost, as compared with
placebo. In addition, the rate of the combined end point of
death or hospitalization was low and similar in both
beraprost sodium and placebo groups (6% vs. 5%, respec-
tively). Possible explanations for these findings include the
high proportion of NYHA functional class II patients at
baseline and the short duration of the study that was not
specifically designed to detect a difference in these secondary
end points.
Cardiopulmonary hemodynamics. Unlike the previous
studies with epoprostenol (18), we did not find statistically
significant improvements in resting hemodynamic variables
even if small favorable trends in the beraprost sodium group
were observed. Possible reasons for explaining these differ-
ences include the greater severity of baseline hemodynamic
changes in earlier epoprostenol trials and the small deteri-
oration we observed in the placebo group.
Safety and tolerability. Despite the high doses of beraprost
sodium used in this study, the safety profile of the drug was
excellent with neither systemic hypotension nor hepatic,
renal or hematologic side effects. Adverse events commonly
observed with all prostacyclin analogues (headache, flush-
ing, jaw pain, diarrhea and nausea) were frequent during the
titration period when the highest possible doses were tested,
while the tolerability of the drug was much better in the
maintenance phase.
Conclusions. Oral beraprost sodium therapy is effective in
improving functional capacity and symptoms in NYHA
functional class II and III patients with PAH and, in
particular, in those with primary pulmonary hypertension.
The benefit/risk ratio of beraprost sodium appears to be
satisfactory. However, further studies are needed to define
the long-term effect of this treatment on morbidity and
mortality of patients with PAH.
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